510 related articles for article (PubMed ID: 31353975)
1. Novel therapies in low- and high-risk myelodysplastic syndrome.
Germing U; Schroeder T; Kaivers J; Kündgen A; Kobbe G; Gattermann N
Expert Rev Hematol; 2019 Oct; 12(10):893-908. PubMed ID: 31353975
[No Abstract] [Full Text] [Related]
2. How we manage adults with myelodysplastic syndrome.
Fenaux P; Platzbecker U; Ades L
Br J Haematol; 2020 Jun; 189(6):1016-1027. PubMed ID: 31568568
[TBL] [Abstract][Full Text] [Related]
3. New Approaches to Myelodysplastic Syndrome Treatment.
Bazinet A; Bravo GM
Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
[TBL] [Abstract][Full Text] [Related]
4. Therapy for lower-risk MDS.
Carraway HE; Saygin C
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):426-433. PubMed ID: 33275714
[TBL] [Abstract][Full Text] [Related]
5. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
Fenaux P; Platzbecker U; Mufti GJ; Garcia-Manero G; Buckstein R; Santini V; Díez-Campelo M; Finelli C; Cazzola M; Ilhan O; Sekeres MA; Falantes JF; Arrizabalaga B; Salvi F; Giai V; Vyas P; Bowen D; Selleslag D; DeZern AE; Jurcic JG; Germing U; Götze KS; Quesnel B; Beyne-Rauzy O; Cluzeau T; Voso MT; Mazure D; Vellenga E; Greenberg PL; Hellström-Lindberg E; Zeidan AM; Adès L; Verma A; Savona MR; Laadem A; Benzohra A; Zhang J; Rampersad A; Dunshee DR; Linde PG; Sherman ML; Komrokji RS; List AF
N Engl J Med; 2020 Jan; 382(2):140-151. PubMed ID: 31914241
[TBL] [Abstract][Full Text] [Related]
6. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Garcia-Manero G
Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
[TBL] [Abstract][Full Text] [Related]
7. Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia.
Kang C; Syed YY
Drugs; 2021 Jun; 81(8):945-952. PubMed ID: 33970460
[TBL] [Abstract][Full Text] [Related]
8. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Balleari E; Kaivers J; Sapena R; Götze K; Müller-Thomas C; Beyne-Rauzy O; Stamatoullas A; Kotsianidis I; Komrokji R; Steensma DP; Fensterl J; Roboz GJ; Bernal T; Ramos F; Calabuig M; Guerci-Bresler A; Bordessoule D; Cony-Makhoul P; Cheze S; Wattel E; Rose C; Vey N; Gioia D; Ferrero D; Gaidano G; Cametti G; Pane F; Sanna A; Germing U; Sanz GF; Dreyfus F; Fenaux P
J Clin Oncol; 2017 May; 35(14):1591-1597. PubMed ID: 28350519
[TBL] [Abstract][Full Text] [Related]
9. Luspatercept in Myelodysplastic Syndromes: Who and When?
Komrokji RS
Hematol Oncol Clin North Am; 2020 Apr; 34(2):393-400. PubMed ID: 32089218
[TBL] [Abstract][Full Text] [Related]
10. Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies.
Molica M; Rossi M
Expert Opin Biol Ther; 2024 Apr; 24(4):233-241. PubMed ID: 38555469
[TBL] [Abstract][Full Text] [Related]
11. Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia.
Feld J; Navada SC; Silverman LR
Leuk Res; 2020 Oct; 97():106430. PubMed ID: 32763582
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion.
Park S; Kelaidi C; Meunier M; Casadevall N; Gerds AT; Platzbecker U
Ann Hematol; 2020 Jan; 99(1):7-19. PubMed ID: 31650290
[TBL] [Abstract][Full Text] [Related]
13. Lowering the boom on lower-risk myelodysplastic syndromes.
Sekeres MA; Patel BJ
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):367-372. PubMed ID: 31808873
[TBL] [Abstract][Full Text] [Related]
14. The lower risk MDS patient at risk of rapid progression.
Mittelman M; Oster HS; Hoffman M; Neumann D
Leuk Res; 2010 Dec; 34(12):1551-5. PubMed ID: 20573398
[TBL] [Abstract][Full Text] [Related]
15. Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents.
Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Komrokji R; Steensma D; Balleari E; Götze KS; Kotsianidis I; Guerci-Bresler A; Stamatoullas A; Sanz GF; Germing U; Fenaux P
Leuk Res; 2020 Dec; 99():106472. PubMed ID: 33212326
[No Abstract] [Full Text] [Related]
16. Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States.
Ma X; Steensma DP; Scott BL; Kiselev P; Sugrue MM; Swern AS
BMJ Open; 2018 Jul; 8(7):e019955. PubMed ID: 30037860
[TBL] [Abstract][Full Text] [Related]
17. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
18. Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts.
Schulz F; Nachtkamp K; Kasprzak A; Gattermann N; Haas R; Germing U
Expert Rev Hematol; 2021 Jun; 14(6):509-516. PubMed ID: 34161752
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years.
Feld J; Belasen A; Navada SC
Expert Rev Anticancer Ther; 2020 Jun; 20(6):465-482. PubMed ID: 32479130
[TBL] [Abstract][Full Text] [Related]
20. New drugs for myeloid neoplasms with ring sideroblasts: Luspatercept vs imetelstat.
Tefferi A
Am J Hematol; 2021 Jul; 96(7):761-763. PubMed ID: 33861878
[No Abstract] [Full Text] [Related]
[Next] [New Search]
